re: mushrooms

Windsor1 - Obviously you have not taken to much time to read who is really on the board of Cbio,I quote "Who does Alan Baker then replace these drug developers with?
2 engineers who also then invited a lawyer onto the board.
Just what a biotech company needs to develop a drug" Have you forgotten Dr Campbell-his profile is listed below.

As you know Xtoll is being reformulated in the US and we were advised this would take at least 6 months to complete.So no new trials can take place until this is complete.
I do not believe the Board is doing nothing as ColinK60 suggested yesterday " just wish this board would get off their butts and do something!"A lot of work has been done to stablise the Company and reduced expenditure to $350k per month instead of approx 1.3 -1.5 Million a month and only necessary scientific staff retained.
When news is released I believe it will be very positive.We have one of Australia's best legal men on the board to advise the company going forward-while the previous board chose not to take advise .

Profile of Dr.Campbell:

Dr James Campbell
Non-executive Director
Dr James Campbell is a senior biotechnology executive with more than 20 years experience in scientific research, research management, management consulting and venture capital. Dr Campbell is a principal of Gemini Biotechnology, a specialist biotechnology advisory services company advising life science companies on M&A, partnering and corporate strategy, and is a founder and director of Vitality Devices Pty Ltd. Dr Campbell was an executive at ChemGenex for 9 years and has served on the investment committee of UniSeed, a $60million pre-seed venture fund, and various state and local government advisory committees concerning biotechnology.